CryoPort (NASDAQ:CYRX) Posts Earnings Results, Misses Estimates By $0.07 EPS

CryoPort (NASDAQ:CYRX) issued its quarterly earnings results on Thursday. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07), Zacks reports. The company had revenue of $50.22 million for the quarter, compared to analyst estimates of $48.66 million. CryoPort had a negative return on equity of 7.20% and a negative net margin of 20.05%.

Here are the key takeaways from CryoPort’s conference call:

• Cryoport reported third-quarter revenue of $50.2 million, up 14% year over year, and raised its 2026 continuing-operations revenue outlook to $197 million–$199 million. Management characterized the outlook as prudent, with fourth-quarter growth expected to continue but potential upside.
• Life Sciences Services revenue rose 18%, including 20% growth in commercial cell and gene therapy activity; the company supports 23 commercial therapies and reported a record pipeline of 788 clinical trials, including 99 in Phase III. Management sees the pipeline and rising therapy adoption as drivers of future commercial growth.
• The company posted a second consecutive quarter of positive adjusted EBITDA, at $1.1 million and $1.8 million better year over year. Management expects further operating leverage as new BioServices capabilities come online, while noting that long-term margin targets remain goals rather than current results.
• Life science products revenue increased 8%, supported by animal-health demand and the Fusion freezer line, although management described animal health as cyclical and said China was stable but not a significant growth market. Four expected 2026 therapy application filings have shifted to 2027, while two potential fourth-quarter approvals have FDA decision dates.

CryoPort Price Performance

Shares of NASDAQ CYRX traded up $3.05 during midday trading on Friday, reaching $19.10. 2,585,565 shares of the stock were exchanged, compared to its average volume of 854,852. CryoPort has a 12 month low of $7.61 and a 12 month high of $19.53. The company has a market capitalization of $967.42 million, a price-to-earnings ratio of -19.69 and a beta of 1.89. The business has a 50-day simple moving average of $16.98 and a two-hundred day simple moving average of $13.46.

Analyst Ratings Changes

CYRX has been the subject of a number of research reports. Guggenheim raised their price target on shares of CryoPort from $16.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, October 1st. BTIG Research upped their price objective on CryoPort from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Weiss Ratings upgraded CryoPort from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, October 8th. Needham & Company LLC lifted their target price on CryoPort from $19.00 to $28.00 and gave the company a “buy” rating in a research note on Friday. Finally, KeyCorp lifted their target price on CryoPort from $17.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.69.

Key Stories Impacting CryoPort

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Third-quarter revenue rose 14% year over year to $50.2 million, topping estimates of $48.66 million. Commercial cell and gene therapy revenue grew 20%; Cryoport supported a record 788 global clinical trials and 23 commercially approved therapies. Cryoport Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to $197 million–$199 million, a key catalyst behind the favorable reaction to results. CryoPort Shares Rise After Q3 Revenue Beat, 2026 Guidance Raise
• Positive Sentiment: Analyst actions added support: Needham raised its price target to $28 from $19 and reiterated Buy, while KeyCorp lifted its target to $20 from $17 and maintained an Overweight rating. Needham Adjusts Price Target KeyCorp Rating
• Negative Sentiment: Adjusted earnings were a loss of $0.25 per share, missing consensus estimates of a $0.18–$0.19 loss and widening from a $0.18 loss a year earlier. The earnings shortfall may temper optimism around the revenue growth and raised outlook. CryoPort Reports Q3 Loss, Tops Revenue Estimates

Insider Activity at CryoPort

In related news, CEO Jerrell Shelton sold 28,800 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $14.91, for a total transaction of $429,408.00. Following the sale, the chief executive officer owned 1,201,814 shares of the company’s stock, valued at approximately $17,919,046.74. This trade represents a 2.34% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.50% of the stock is currently owned by corporate insiders.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of biological materials, including cell and gene therapies, vaccines, biologics, reproductive materials and other temperature-sensitive products.

Its offerings include cryogenic and refrigerated shipping containers, biological material storage, transportation logistics, shipment monitoring and related supply chain management services.